The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.

StocksMediumUpdated×3•Originally published 4 May 2026•Updated 6 May 2026•

1 min read

Vertex Pharmaceuticals Q1 Revenue Climbs 8%, Reaffirms Full-Year 2026 Guidance

Key Facts

1Vertex Pharmaceuticals total revenue rose 8% to $2.99 billion in the first quarter of 2026.

2The company reaffirmed its full-year 2026 revenue guidance of $12.95–$13.1 billion.

Vertex Pharmaceuticals reported robust Q1 2026 results, with total revenue rising 8% to $2.99 billion, driven by its cystic fibrosis portfolio and new contributions from CASGEVY and JOURNAVX. Management reaffirmed its full-year 2026 revenue guidance of $12.95 billion to $13.1 billion, signaling confidence in its growth trajectory. In related sector news, Rigel Pharmaceuticals reported increased net product sales for TAVALISSE, REZLIDHIA, and GAVRETO for the quarter ending March 31, 2026. However, Rigel also announced the termination of its global strategic partnership with Lilly and an amendment to its credit agreement with MidCap. Meanwhile, Vertex continues to advance its povetacicept program and pursue label expansions for key treatments. Investors are closely monitoring these operational milestones and shifts in strategic partnerships as key drivers for biotech stock performance.

29 days ago

Version History

2 additional sources confirmed this story

Version 329 days ago

What changed: The story was updated to include Rigel Pharmaceuticals' financial results, including sales growth and the termination of its partnership with Lilly.

Version 229 days ago

What changed: Added information regarding KeyCorp's disclosure of intent to sell shares acquired via 2017 stock options.

Version 1about 1 month ago

What changed: Updated the story to include specific pipeline advancements regarding the povetacicept program and regulatory expansion plans for ALYFTREK, TRIKAFTA, and CASGEVY.